Two Studies Reveal Differences In RealWorld Treatment Patterns In Rheumatoid Arthritis Patients Taking REMICADEÂ infliximab Compared To CTP13 infliximab biosimilar

WASHINGTON Nov. 14 2016 PRNewswire Janssen Biotech Inc. announced today findings from two claims database studies examining treatment patterns in patients with rheumatoid arthritis RA. The first study compared treatment patterns in patients newly beginnin...